Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: Systematic review and meta-analysis of randomized controlled trials

Pain Medicine

Volumn 9, Issue 6, 2008, Pages 634-659

  Mcnicol, Ewan ^a   Boyce, David B ^a   Schumann, Roman ^a   Carr, Daniel ^b,c  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Javelin Pharmaceuticals Inc   (United States)

Author keywords

Constipation; Meta analysis; Opioid antagonist; Opioid induced bowel dysfunction; Postoperative ileus

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; CODEINE; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALBUPHINE; NALOXONE; OPIATE; PARACETAMOL; PENTAZOCINE; PLACEBO;

ABDOMINAL PAIN; ABDOMINAL SWELLING; ACUTE DISEASE; AGITATION; ANXIETY; ARTICLE; BLOATING; BLOOD PRESSURE; CHRONIC DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DATA EXTRACTION; DEFECATION DISORDER; DEFECATION URGENCY; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; ENTEROPATHY; HEART RATE; HUMAN; HYPOVENTILATION; ILEUS; INFORMATION RETRIEVAL; INTESTINE TRANSIT TIME; MEDLINE; META ANALYSIS; MORBIDITY; NAUSEA; NAUSEA AND VOMITING; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING;

ANALGESICS, OPIOID; ANIMALS; GASTROINTESTINAL DISEASES; HUMANS; NARCOTIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID, MU;

EID: 50249107478     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2007.00335.x     Document Type: Article

References (49)

1. Pasero C, Portenoy RK, McCaffery M. Opioid analgesics. In: McCaffery M, Pasero C, eds. Pain, 2nd edition. St. Louis, MO: Mosby; 1999: 165-299.
2. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182 (suppl): 11S-8S.
3. Dickerson ED, Benedetti C, Davis MP, et al. Palliative Care Pocket Consultant. Columbus, OH: Janoski Advertising Design; 1999.
4. Portenoy RK. Management of common opioid side effects during long-term therapy of cancer pain. Ann Acad Med Singapore 1994; 23: 160-70.
5. McNicol E, Horowicz-Mehler N, Fisk R, et al. Management of opioid side effects in cancer-related and chronic noncancer pain-A systematic review. J Pain 2003; 4: 231-56.
6. Kehlet H, Holte K. Review of postoperative ileus. Am J Surg 2001; 182 (suppl): 3S-10S.
7. Kehlet H. Postoperative ileus. Gut 2000; 47 (suppl): Iv85-6.
8. Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery. Surg Endosc 2006; 20: 64-70.
9. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies. Drugs 2003; 63: 649-71.
10. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
11. Review Manager Software (RevMan), Version 4.2.8 For Windows. Oxford, England: The Cochrane Collaboration, 2005. CD-ROM and Internet.
12. Cook RJ, Sackett DL. The number needed to treat: A clinically useful measure of treatment effect. BMJ 1995; 310: 452-4.
13. McQuay H, Moore R. An Evidence-Based Resource for Pain Relief. Oxford: Oxford University Press; 1998.
14. Sutton AJ, Abrams KR, Jones DR, et al. Meta-analysis of survival data. In: Cressie NAC, Fisher NI, Johnstone IM, et al., eds. Methods for Meta-Analysis in Medical Research. Chichester: John Wiley & Sons, Ltd.; 2000: 277-85.
15. Higgins JPT, Green S, eds. Guide to the contents of a protocol and review. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. [Updated May 2005]; Section 3. In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd; 2005: 37-57.
16. Deeks JJ, Higgins JPT, Altman DG, eds. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. [Updated May 2005]; Section 8. In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd; 2005: 97-166.
17. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: A double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996; 59: 469-75.
18. Yuan CS, Foss JF, Osinski J, et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997; 61: 467-75.
19. Yuan CS, Foss JF, O'Connor M, Karrison T. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 2000; 67: 398-404.
20. Yuan CS, Wei G, Foss JF, O'Connor M, et al. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: A double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 2002; 300: 118-23.
21. Liu SS, Hodgson PS, Carpenter RL, Fricke JR Jr. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther 2000; 68: 66-71.
22. Freye E, Helle G. Der Agonist-Antagonist Nalbuphin verlangert die gastro-coekale Transitzeit und induziert kurzfristig Schmerzen nach Neuroleptanaesthesie mit Fentanyl. Eine Vergleichsuntersuchung zu Plazebo. [The agonist-antagonist nalbuphine prolongs gastro-cecal transit time and induces short-term pain following neuroleptanesthesia using fentanyl. A comparative study using a placebo]. Anaesthesist 1988; 67: 440-5.
23. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized controlled trial. JAMA 2000; 283: 367-72.
24. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996; 10: 135-44.
25. Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: A peripheral mechanism in humans. Anesthesiology 1997; 87: 765-70.
26. Barr WH, Nguyen P, Slattery M, et al. ADL 8-2698 reverses opioid induced delay in colonic transit. Clin Pharmacol Ther 2000; 67: 91 (Abstract).
27. Gonenne J, Camilleri M, Ferber I, et al. Effect of alvimopan and codeine on gastrointestinal transit: A randomized controlled study. Clin Gastroenterol Hepatol 2005; 3: 784-91.
28. Hawkes ND, Richardson C, Evans BK, et al. Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine. Aliment Pharmacol Ther 2001; 15: 625-30.
29. Nimmo WS, Heading RC, Wilson J, Prescott LF. Reversal of narcotic-induced delay in gastric emptying and paracetamol absorption by naloxone. BMJ 1979; 2: 1189.
30. Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005; 48: 1114-29.
31. Taguchi A, Sharma N, Saleem RM, et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 2001; 245: 935-40.
32. Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting mu opioid antagonist-Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004; 240: 728-35.
33. Lee J, Shim JY, Choi JH, et al. Epidural naloxone reduces intestinal hypomotility but not analgesia of epidural morphine. Can J Anaesth 2001; 48: 54-8.
34. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002; 23: 48-53.
35. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-A 21-day treatment-randomized clinical trial. J Pain 2005; 6: 184-92.
36. Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004; 48: 2787-92.
37. Carr DB, Cousins MJ. Spinal route of analgesia. Opioids and future options. In: Cousins MJ, Bridenbaugh PO, eds. Neural Blockade in Clinical Anesthesia and Management of Pain, 3rd edition. Philadelphia, PA: Lippincott-Raven Publishers; 1998: 915-83.
38. Liu SS, Carpenter RL, Mackey DC, et al. Effects of perioperative analgesic technique on rate of recovery after colon surgery. Anesthesiology 1995; 83: 757-65.
39. Person B, Wexner SD. The management of postoperative ileus. Curr Probl Surg 2006; 43: 12-65.
40. Fakata KL, Lipman AG. Gastrointestinal opioid physiology and pharmacology. In: Yuan CS, ed. Handbook of Opioid Bowel Syndrome. Binghamton, NY: The Haworth Medical Press; 2005: 7-28.
41. Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: A comparison between transdermal fentanyl and oral morphine. Palliat Med 2000; 14: 111-9.
42. Meissner W, Dohrn B, Reinhart K. Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia. Crit Care Med 2003; 31: 776-80.
43. Meissner W, Hartmann M, Kahler G, Brauer M. Der Einfluss von enteralem Naloxon auf die Inzidenz von Gastritis und Osophagitis bei opioidbehandelten Intensivpatienten: Doppelblinde plazebokontrollierte Studie [Effect of enteral naloxone on the incidence of gastritis and esophagitis in mechanically ventilated patients]. Anasthesiol Intensivmed Notfallmed Schmerzther 2004; 39: 538-41.
44. Cepeda MS, Alvarez H, Morales O, Carr DB. Addition of ultralow dose naloxone to postoperative morphine PCA: Unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain 2004; 107: 41-6.
45. Winpenny JP. Lubiprostone. Idrugs 2005; 8: 416-22.
46. Ferraz AA, Cowles VE, Condon RE, et al. Nonopioid analgesics shorten the duration of postoperative ileus. Am Surg 1995; 61: 1079-83.
47. Jadad AR. Meta-analysis in pain relief: A valuable but easily misused tool. Curr Opin Anaesthesiol 1996; 9: 426.
48. Naylor CD. Meta-analysis and the meta-epidemiology of clinical research: Meta-analysis is an important contribution to research and practice but it's not a panacea (Editorial). BMJ 1997; 317: 617-9.
49. Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316: 450-5.